Brian Ball

Brian Ball, M.D. is an Assistant Professor in the Division of Leukemia within the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. He specializes in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with a research focus on understanding the molecular mechanisms of resistance to current leukemia treatments.

Dr. Ball's research interests center on acute myeloid leukemia, myelodysplastic syndromes, and the molecular mechanisms mediating resistance to leukemia therapies. His work particularly focuses on overcoming resistance to apoptosis therapies, as evidenced by his American Society of Clinical Oncology Young Investigator Award. His research has significant clinical implications for improving treatment outcomes in patients with myeloid malignancies.

His recent publications (2022-2023) demonstrate a strong focus on venetoclax-based therapies, FLT3 and IDH inhibitors, and molecular mechanisms in AML and MDS. The research shows evolving trends toward combination therapies, molecularly targeted approaches, and understanding treatment resistance mechanisms in myeloid malignancies.

• Mortimer J. Lacher Fellowship Funding from the Lymphoma Foundation (2020)
• Memorial Sloan Kettering Cancer Center Chief Fellow (2019-2020)
• American Society of Hematology Abstract Achievement Award (2019, 2016)
• Yale/Stanford Global Health Scholar Recipient (2017)
• Alpha Omega Alpha (2014)

Dr. Ball maintains an active clinical practice with exceptional patient satisfaction ratings (4.9/5 average), particularly noted for his ability to explain complex medical information clearly. His work bridges clinical care and translational research, focusing on improving outcomes for patients with myeloid malignancies through both direct patient care and innovative research approaches.